Stock Updates

A look at a High Market Cap Stock: Teva Pharmaceutical Industries Limited, TEVA

Teva Pharmaceutical Industries Limited, TEVA is in the exchange NYSE and its industry is Drug Manufacturers – Other in the sector of Healthcare. Based in Israel, Teva Pharmaceutical Industries Limited, TEVA  has a market cap of 51383.83. Since its IPO date on the 3/26/1990, Teva Pharmaceutical Industries Limited, TEVA performance year to date is -22.78%. Today Teva Pharmaceutical Industries Limited, TEVA has gained -0.10%, with a current price of 50.

Ownership of the company is 2.70% for insider ownership while institutional ownership is 60.00%. The management of the company have seen the company have a payout ratio of 70.10%. Return of assets are at 3.30%, with return on investment at 5.70%.

In terms of debt levels and profit levels, Teva Pharmaceutical Industries Limited, TEVA is seeing a long-term debt/equity of 0.28. While Total debt/equity is 0.34. With a profit margin of 8.70%, this is combined with a gross margin of 58.10%, and operating margin of 19.30%. Teva Pharmaceutical Industries Limited ability to meet debt levels, with a current ratio of 1.3, while the quick ratio is 1.

For the last year Teva Pharmaceutical Industries Limited, TEVA has seen a EPS growth of -48.90%. A performance for the year of -16.77%. The 52-week high is -29.22%, and the 52-week low is 4.14%. The average volume for Teva Pharmaceutical Industries Limited, TEVA is 2412303.

With a target price of 71.68, can Teva Pharmaceutical Industries Limited, TEVA reach this target? Looking at the value indicators of Teva Pharmaceutical Industries Limited, TEVA. Teva Pharmaceutical Industries Limited has a P/E of 26.05 and a forward P/E of 8.4. Perhaps the more useful indicator than P/E, is PEG which has a value of 4.99. Teva Pharmaceutical Industries Limited also has a P/S and a P/B of 2.64 and 1.5 respectively. For P/cash, Teva Pharmaceutical Industries Limited has a value of 8.62, while it is *TBA for P/free cash flow.

At the current price of 50, Teva Pharmaceutical Industries Limited has a dividend yield of 2.72%. We see a return on equity of 6.60%.

Looking more long-term Teva Pharmaceutical Industries Limited, is projected to get an EPS growth for the next five years of 5.22%. In the short-term an EPS growth of 13.58% in the next year is forecasted. This is after a EPS growth of -48.90% for this year and for the last five years a -13.10% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment